Background {#Sec1}
==========

Human cancer is a major cause of death in the world, and it is estimated that the number of new cases will increase to more than 15 million in the coming decade, creating a substantial worldwide public health burden \[[@CR1], [@CR2]\]. Various factors, such as genetic and environmental influences, are associated with cancer prognosis. However, the exact etiology and mechanism of carcinogenesis have not yet been clearly elucidated. In recent years, it has become well-accepted that intrinsic factors, such as host genetic susceptibility, may play important roles in the process of cancer development \[[@CR3], [@CR4]\], and an increasing number of studies have focused on the association between genetic factors and cancer susceptibility.

Hypoxia-inducible factor 1 (HIF-1) is a transcriptional activator that functions as a critical regulator of oxygen homeostasis. It is a heterodimer composed of two subunits, HIF-1α and HIF-1β, which dimerize and bind to DNA via the basic helix-loop-helix Per/Arnt/Sim (bHLH-PAS) domain \[[@CR5], [@CR6]\]. HIF-1α expression is induced in hypoxic cells, and its level exponentially increase when the cells are exposed to O~2~ concentration of less than 6%. Under hypoxic condition, HIF-1α ubiquitination decreases dramatically, resulting in an accumulation of the protein, while under normoxic condition, HIF-1α is rapidly degraded through von Hippel-Lindau (VHL)-mediated ubiquitination and proteasomal degradation \[[@CR7]--[@CR10]\]. HIF-1 has also been suggested to play an important role in tumor development, progression and metastasis, and HIF-1 can activate the transcription of more than 60 target genes that are involved in crucial aspects of cancer establishment, including cell survival, glucose metabolism, angiogenesis and invasion \[[@CR11], [@CR12]\].

The HIF-1α gene is located on chromosome 14q21-24, and recent studies have shown that there are a total of 35 common single nucleotide polymorphisms (SNPs) throughout the HIF-1α gene in Caucasian and Asian population \[[@CR13]--[@CR15]\]. Two important SNPs in exon 12 of the HIF-1 gene, HIF-1α C1772T (rs11549465) and HIF-1α G1790A (rs11549467), lead to amino acid substitution of proline to serine at position 582 and alanine to threonine at position 588 of the protein, respectively \[[@CR8], [@CR16], [@CR17]\]. These two polymorphisms have been demonstrated to be functionally meaningful, resulting in increased transcriptional activity of HIF-1α \[[@CR14], [@CR18]\]. Previous studies have shown that the overexpression of HIF-1α is significantly associated with cell proliferation, increased tumor susceptibility, tumor size, lymph node metastasis and prognosis \[[@CR19], [@CR20]\].

In recent years, the HIF-1α gene has been a research focus in the scientific community, and many epidemiological studies have been performed to assess the association between HIF-1α C1772T/G1790A polymorphisms and cancer susceptibility. However, the results of the different studies are conflicting. Hence, we performed a meta-analysis of all of the eligible studies to clarify the role of HIF-1α C1772T/G1790A polymorphisms in cancer development.

Methods {#Sec2}
=======

Study eligibility and validity assessment {#Sec3}
-----------------------------------------

We performed a computerized literature search of the PubMed and Web of Science databases to identify all of the relevant studies of cancer that contained sufficient genotyping data for at least one of the two polymorphisms, HIF-1α C1772T or HIF-1α G1790A. The search strategy was designed by two researchers and included the following keywords: "HIF-1 OR hypoxia-inducible factor-1" and "polymorphism", and the last search was updated on September 20th, 2013. To obtain all eligible publications, we also manually reviewed the references of the selected articles to identify other potential eligible publications. Articles investigating the association between cancer risk and the HIF-1α polymorphisms were identified with no language restriction.

Inclusion criteria {#Sec4}
------------------

The studies selected were required to meet the following criteria: 1) evaluate the association between the HIF-1α C1772T and/or HIF-1α G1790A polymorphisms and cancer risk; 2) use a human case-control design; 3) contain sufficient published data for the estimation of an odds ratio (OR) with a 95% confidence interval (CI).

Data extraction {#Sec5}
---------------

Data were extracted from all of the eligible publications by two investigators (Yan and Chen) independently, according to the inclusion criteria listed above. Disagreements between the two investigators were resolved by discussion until a consensus was reached. The following information was extracted from each of the included publications: the first author's name, publication data, country of origin, ethnicities of the sample population (categorised as Asians, Caucasians and Mixed), cancer type, source of control group (population- or hospital-based controls), total number of cases and controls, and the number of cases and controls with the HIF-1α C1772T/G1790A polymorphisms.

Statistical methods {#Sec6}
-------------------

The strength of the association between the HIF-1α C1772T/HIF-1α G1790A polymorphisms and cancer risk was measured by ORs with 95% CIs. The statistical significance of the pooled OR was calculated by the Z test, a *P* \< 0.05 was considered to be statistically significant (*P*-values were two sided). For HIF-1α C1772T polymorphism, we examined the overall ORs and compared the cancer incidence using the allelic model (T versus C), homozygote model (TT versus CC), heterozygote model (TC versus CC), dominant model (TT + TC versus CC), recessive model (TT versus TC + CC). For HIF-1α G1790A polymorphism, we evaluated the risk in the allelic model (A versus G), homozygote model (AA versus GG), heterozygote comparison model (GA versus GG), dominant models (AA + AG versus GG), and recessive model (AA versus AG + GG). Subgroup analyses were also conducted by ethnicity, cancer type ("other cancer groups" means any cancer types with less than two separate publications) and source of controls. Statistical heterogeneity was estimated by a chi-square based Q-test, and when *P* \< 0.05, the heterogeneity was considered to be significant. We combined all of the values from each individual study using the fixed-effect model and the random-effect model. When *P* \> 0.05, the effects were assumed to be homogenous, and the fixed-effect model (the Mantel-Haenszel method) was used \[[@CR21]\]. When *P* \< 0.05, the random-effect model (the DerSimonian and Laird method) was more appropriate \[[@CR22]\]. The inter-study variance I^2^ (I^2^ = 100% × (Q-df)/Q) was used to quantitatively estimate the heterogeneity, and the percentage of I^2^ was used to describe the extent of the heterogeneity, I^2^ \< 25%, 25-75% and \>75% represent low, moderate and high inconsistency, respectively \[[@CR23], [@CR24]\]. In addition, we performed sensitivity analyses to evaluate the potential biases of the results in our meta-analyses. The Hardy-Weinberg equilibrium (HWE) of the controls for each study was also calculated using a goodness-of-fit test (chi-square or Fisher's exact test) and *P* \< 0.05 was considered to be statistically significant. Sensitivity analyses were carried out to assess the stability of the results by conducting analysis of studies with controls in HWE. Finally, the Begg's funnel plot and Egger's test were utilised to estimate the publication bias \[[@CR25]\]. All analyses were conducted by the software Stata (Version 11; Stata Corporation, College Station, Texas, USA). All *P*-values were two-sided and a *P* of \< 0.05 was considered to be statistically significant.

Results {#Sec7}
=======

Studies selected {#Sec8}
----------------

Through the literature search and selection, a total of 40 eligible studies met the inclusion criteria and were included in our meta-analysis. One study (Konac *et al.*) \[[@CR26]\] provided data on three types of cancer (cervical cancer, ovarian cancer, and endometrial cancer) and both polymorphisms; therefore, we have grouped them as one in the meta-analyses of all subjects except when stratified by cancer type. Thus, each type of cancer in this study was treated as a separated study in sub-group analyses. Among the 40 eligible studies, 40 studies, representing 10869 cases and 14289 controls, were ultimately analyzed for the HIF-1α C1772T polymorphism \[[@CR8], [@CR17], [@CR26]--[@CR63]\], and 30 studies, representing 7177 cases and 10442 controls, were analyzed for the HIF-1α G1790A polymorphism \[[@CR8], [@CR17], [@CR26], [@CR29]--[@CR31], [@CR33]--[@CR35], [@CR37]--[@CR43], [@CR45]--[@CR48], [@CR50], [@CR52]--[@CR57], [@CR59], [@CR62], [@CR63]\]. The literature search and study selection procedure are shown in Figure [1](#Fig1){ref-type="fig"}. Of the 40 studies on the HIF-1α C1772T polymorphism, 6 studies were conducted on prostate cancer, 6 studies on breast cancer, 3 studies on lung cancer, 4 studies on colorectal cancer, 4 studies on renal cancer, 4 studies on oral cancer and 12 studies on other cancers. Among these eligible studies, 20 were studies on Asians, 16 were studies on Caucasians and 4 studies were performed on a population of mixed ethnicity. The control sources were population-based in 17 studies and hospital-based in 23 studies. For the HIF-1α G1790A polymorphism, 15 of the 30 eligible studies were performed in Asian populations, 13 studies were performed in Caucasian populations and 2 studies were performed in a mixed ethnicity population. Of these studies, 4 studies were conducted on breast cancer, 3 studies on lung cancer, 4 studies on oral cancer, 3 studies on prostate cancer, 3 studies on cervical cancer, 2 studies on pancreatic cancer, 2 studies on colorectal cancer, 4 studies on renal cancer and 7 studies on other cancers. The control sources were population-based in 17 studies and hospital-based in 13 studies. The genotype frequency data of the HIF-1α C1772T and HIF-1α G1790A polymorphisms were extracted from all of these eligible publications. For the HIF-1α C1772T polymorphism, the distributions of the genotypes in the control groups in 11 studies were not in HWE \[[@CR17], [@CR50], [@CR51], [@CR53], [@CR54], [@CR56]--[@CR58], [@CR60]--[@CR62]\]. For the HIF-1α G1790A polymorphism there was 1 study not in HWE \[[@CR62]\]. The main characteristics of the eligible studies in the meta-analysis are listed in Table [1](#Tab1){ref-type="table"}.Figure 1**Study flow-chart illustrating the literature search and eligible study selection process.**

###### 

**Characteristics of studies included in the meta-analysis**

  First author   Year     Country      Ethnicity   Cancer type       Gene type   Source of controls   Cases   Controls   Case   Control    HWE                              
  -------------- -------- ------------ ----------- ----------------- ----------- -------------------- ------- ---------- ------ ---------- ------- ------- ---------- ----- --------
  Clifford       2001     UK           Caucasian   Renal             C1772T      PB                   48      143        42     6          0       110     27         6     0.02
                                                                     G1790A      PB                   48      144        47     1          0       140     4          0     0.87
  Tanimoto       2003     Japan        Asian       HNSCC             C1772T      PB                   55      110        45     10         0       98      12         0     0.55
                                                                     G1790A      PB                   55      110        51     4          0       101     9          0     0.65
  Kuwai          2004     Japan        Asian       Colorectal        C1772T      PB                   100     100        100    0          0       89      11         0     0.56
  Ollerenshaw    2004     UK           Caucasian   Renal             C1772T      PB                   160     162        16     54         90      1       90         71    0.001
                                                                     G1790A      PB                   146     288        65     67         14      239     39         10    0.001
  Ling           2005     China        Asian       Esophageal        C1772T      HB                   95      104        84     11         0       93      11         0     0.57
  Chau           2005     USA          Caucasian   Prostate          C1772T      PB                   196     196        161    29         6       179     14         3     0.002
  Fransen        2006     Sweden       Caucasian   Colorectal        C1772T      PB                   198     258        167    28         3       213     43         2     0.92
  Fransen        2006     Sweden       Caucasian   Colorectal        G1790A      PB                   198     256        189    9          0       247     9          0     0.77
  Konac          2007     Turkey       Caucasian   Cervical          C1772T      HB                   32      107        10     14         8       68      37         2     0.23
                                                                     G1790A      HB                   32      107        32     0          0       107     0          0     0.99
                                       Caucasian   Ovarian           C1772T      HB                   49      107        34     14         1       68      37         2     0.23
                                                                     G1790A      HB                   49      107        47     2          0       107     0          0     0.99
                                       Caucasian   Endometrial       C1772T      HB                   21      107        4      12         5       68      37         2     0.23
                                                                     G1790A      HB                   21      107        21     0          0       107     0          0     0.99
  Li             2007     USA          mixed       Prostate          C1772T      PB                   1041    1234       818    209        14      995     221        18    0.16
                                                                     G1790A      PB                   1066    1264       1053   13         0       1247    17         0     0.81
  Orr-Urtreger   2007     Israel       Caucasian   Prostate          C1772T      PB                   402     300        287    99         16      217     80         3     0.14
                                                                     G1790A      PB                   200     300        198    2          0       298     2          0     0.95
  Apaydin        2008     Turkey       Caucasian   Breast            C1772T      PB                   102     102        79     21         2       68      29         5     0.42
                                                                     G1790A      PB                   102     102        102    0          0       98      4          0     0.84
  Lee            2008     Korea        Asian       Breast            C1772T      PB                   1332    1369       1207   119        6       1245    123        1     0.25
  Kim            2008     Korea        Asian       Breast            C1772T      HB                   90      102        81     8          1       93      9          0     0.64
                                                                     G1790A      HB                   90      102        87     3          0       94      7          1     0.06
  Nadaoka        2008     Japan        Asian       Bladder           C1772T      HB                   219     461        197    21         1       419     42         0     0.35
                                                                     G1790A      HB                   219     461        204    13         2       421     40^\*^     \-    0.46
  Jacobs         2008     USA          mixed       Prostate          C1772T      HB                   1420    1450       1156   252        12      1138    284        28    0.04
  Horree         2008     Netherland   Caucasian   Endometrial       C1772T      PB                   58      559        50     5          3       463     84         12    0.01
  Naidu          2009     Malaysia     Asian       Breast            C1772T      PB                   410     275        294    100        16      222     50         3     0.92
                                                                     G1790A      PB                   410     275        332    72         6       232     41         2     0.90
  Chen           2009     Taiwan       Asian       Oral              C1772T      PB                   174     347        163    10         1       334     13         0     0.72
                                                                     G1790A      PB                   174     347        153    20         1       333     14         0     0.70
  Konac          2009     Turkey       Caucasian   Lung              C1772T      PB                   141     156        110    31         0       111     43         2     0.34
                                                                     G1790A      PB                   141     156        141    1          0       154     2          0     0.94
  Morris         2009     UK           Caucasian   Renal             C1772T      PB                   332     313        290    39         3       262     46         5     0.08
                                                                     G1790A      PB                   325     309        313    10         2       294     15         0     0.66
  Foley          2009     Ireland      Caucasian   Prostate          C1772T      PB                   95      188        65     30         0       175     13         0     0.62
  Li             2009     China        Asian       Gastric           C1772T      HB                   87      106        83     4          0       93      13         0     0.50
                                                                     G1790A      HB                   87      106        74     13         0       100     6          0     0.76
  Munoz-                                                                                                                                                                    
  Guerra         2009     Spain        Caucasian   Oral              C1772T      PB                   70      148        57     6          7       113     27         8     \<0.01
                                                                     G1790A      PB                   64      139        40     21         3       130     9          0     0.69
  Kim            2010     Korea        Asian       Cervical          C1772T      HB                   199     214        177    22         0       187     27         0     0.32
                                                                     G1790A      HB                   199     213        187    12         0       200     12         1     0.10
  Shieh          2010     Taiwan       Asian       Oral              C1772T      HB                   305     96         282    23         0       89      7          0     0.71
                                                                     G1790A      HB                   305     96         281    24         0       89      7          0     0.71
  Knechtal       2010     Austria      Caucasian   Colorectal        C1772T      PB                   368     2156       291    77^\*\*^   \-      1773    383^\*^    \-    \>0.05
                                                                     G1790A      PB                   367     2156       356    11^\*^     \-      2080    76^\*^     \-    \>0.05
  Hsiao          2010     Taiwan       Asian       Hepatocellul-ar   C1772T      HB                   102     347        94     8          0       334     13         0     0.72
                                                                     G1790A      HB                   102     347        87     15         0       333     14         0     0.70
  Xu             2011     China        Asian       Glioma            C1772T      HB                   150     150        121    27         2       135     14         1     0.35
  Putra          2011     Japan        Asian       Lung              C1772T      PB                   83      110        74     9          0       98      12         0     0.55
                                                                     G1790A      PB                   83      110        72     9          2       101     9          0     0.65
  Kang           2011     Korea        Asian       Colorectal        C1772T      PB                   50      50         46     4^\*\*^    \-      38      12^\*\*^   \-    \<0.01
  Wang           2011     China        Asian       Pancreatic        C1772T      HB                   263     271        209    54         0       242     29         0     0.35
                                                                     G1790A      HB                   263     271        198    65         0       249     22         0     0.49
  Zagouri        2012     Greece       Caucasian   Breast            C1772T      HB                   113     124        98     15         0       107     17         0     0.41
  Kuo            2012     Taiwan       Asian       Lung              C1772T      HB                   285     300        153    94         38      216     73         11    0.13
                                                                     G1790A      HB                   285     300        150    94         41      215     74         11    0.15
  Qin            2012     China        Asian       Renal             C1772T      HB                   620     623        572    46         2       578     43         2     0.22
                                                                     G1790A      HB                   620     623        575    45         0       584     39         0     0.42
  Li             2012     China        Asian       Prostate          C1772T      HB                   662     716        612    48         2       659     57         0     0.27
                                                                     G1790A      HB                   662     716        614    47         1       685     31         0     0.55
  Alves          2012     Brazil       mixed       Oral              C1772T      PB                   40      88         0      1          39      0       85         3     \<0.01
                                                                     G1790A      PB                   40      88         2      1          37      81      7          0     0.70
  Ruiz-Tovar     2012     Spain        Caucasian   Pancreatic        C1772T      PB                   59      152        47     1          11      116     28         8     0.002
                                                                     G1790A      PB                   59      152        54     2          3       142     10         0     0.68
  Fu             2013     China        Asian       Cervical          C1772T      HB                   518     553        467    49         2       492     60         1     0.55
                                                                     G1790A      HB                   509     553        489    20         0       510     42         1     0.89
  Ribeiro        2013     Portugal     Caucasian   Breast            C1772T      PB                   96      74         74     21         1       61      7          4     0.001
                                                                     G1790A      PB                   96      74         96     0          0       74      0          0     0.99
  Mera-                                                                                                                                                                     
  Menendez       2013     Spain        Caucasian   Glottic                                                                                                                  
  larynx         C1772T   HB           118         148               85          18                   15      113        27     8          0.001                            
                                                                     G1790A      HB                   111     139        107    4          0       130     9          0     0.69
  Total                                                              C1772T                           10869   14289      8994   1568       307     12181   1897       211   
                                                                     G1790A                           7117    10442      6416   589        112     9922    494        26    

W: wide type alleles (1772C or 1790G); M: mutant type alleles (1772 T or 1790A); HWE: Hardy-Weinberg Equilibrium; PB: population based; HB: hospital based.

Mixed: Caucasian and African-American; HNSCC: head and neck squamous cell carcinoma.

\*Frequency of genotypes "AA + AG"; \*\*Frequency of genotypes "TT + TC".

Quantitative data synthesis {#Sec9}
---------------------------
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For HIF-1α G1790A polymorphism, as shown in Table [3](#Tab3){ref-type="table"}, the association between the HIF-1α G1790A polymorphism and increased cancer risk was significant for the pooled ORs under all of the genetic models (AA *vs*. GG: OR = 5.11, 95% CI = 2.08-12.56; GA *vs.* GG: OR = 1.45, 95% CI = 1.05-1.99; AA + AG *vs.* GG: OR = 1.63, 95% CI = 1.16-2.30; AA *vs.* GA + GG: OR = 4.41, 95% CI = 1.80-10.84; A *vs.* G: OR = 1.77, 95% CI = 1.23-2.25). In the subgroup analysis by cancer type, a significant association was observed in lung cancer (AA *vs.* GG: OR = 5.42, 95% CI = 2.74-10.70; GA *vs.* GG: OR = 1.72, 95% CI = 1.22-2.41; AA + AG *vs.* GG: OR = 2.14, 95% CI = 1.56-2.94; AA *vs.* GA + GG: OR = 4.52, 95% CI = 2.31-8.83; A *vs.* G: OR = 2.27, 95% CI = 1.74-2.95), pancreatic cancer (AA + AG *vs.* GG: OR = 3.14, 95% CI = 1.99-2.97; A *vs*. G: OR = 3.08, 95% CI = 1.98-4.78) and renal cancer (AA *vs.* GA + GG: OR = 3.09, 95% CI = 1.38-6.92). When the data were stratified by ethnicity, significantly increased cancer risk was observed in Asian population and Caucasian population. When the studies were stratified by the source of controls, a significant association was observed for population-based controls under the homozygote model, the dominant comparison model and the allelic model. Sensitivity analyses were conducted after the removal of the studies with controls not in HWE, the results for the HIF-1α G1790A polymorphism were similar to those when the studies with controls not in HWE were included. Table [3](#Tab3){ref-type="table"} shows the main results of this pooled analysis for the HIF-1α G1790A polymorphism. Figure [3](#Fig3){ref-type="fig"} shows the forest plot of the association between cancer risk and the HIF-1α G1790A polymorphism under the dominant model.Table 3**Meta-analysis of the HIF-1α G1790A polymorphism and cancer risk**VariablesAA ***vs.***GGGA ***vs***. GGAA + AG ***vs.***GGAA ***vs***.GA + GGA ***vs.***G***Study**Case/control**I*** ^***2***^***Phet**OR (95% CI)**Case/control**I*** ^***2***^***Phet**OR (95% CI)**Case/control**I*** ^***2***^***Phet**OR (95% CI)**Case/control**I*** ^***2***^***Phet**OR (95% CI)**Case/control**I*** ^***2***^***Phet**OR (95% CI)***Overall306538/9948570.015.11 (2.08-12.56)^\*^7005/1044277\<0.0011.45 (1.05-1.99)^\*^7117/1044283\<0.0011.63 (1.16-2.30)^\*^7117/10442580.014.41 (1.80-10.84)^\*^14234/2088486\<0.0011.77 (1.23-2.25)^\*^Overall in HWE296449/9699610.0035.14 (1.67-15.86)^\*^6873/1013869\<0.0011.35 (1.01-1.81)^\*^6971/1015479\<0.0011.53 (1.10-2.12)^\*^6971/10154600.0044.80 (1.58-14.55)^\*^13942/2030885\<0.0011.70 (1.17-2.46)^\*^Cancer typeBreast4623/50100.341.44 (0.38-5.44)692/550530.121.03 (0.70-1.52)698/553600.081.05 (0.72-1.53)698/55300.361.41 (0.37-5.40)1396/1466650.561.07 (0.76-1.52)Cervical3708/81900.990.35 (0.04-3.39)740/871570.130.62 (0.40-0.98)740/837510.150.60 (0.38-0.94)740/83700.990.36 (0.04-3.4501480/1746420.190.59 (0.38-0.91)Oral4517/633750.0272.11 (2.08-2502.44)^\*^542/670700.023.17 (1.26-7.92)^\*^583/67092\<0.0017.92 (1.58-39.64)^\*^583/670750.0258.05 (1.70-1985.77)^\*^1166/1340960.019.66 (1.31-71.15)^\*^Prostate31866/2230\-\--1927/228010.371.42 (0.97-2.07)1928/228070.341.44 (0.98-2.10)1928/2280\-\--3856/4560100.331.45 (0.99-2.11)Renal41016/126700.955.10 (2.21-11.73)1123/135492\<0.0011.51 (0.45-5.05)^\*^1139/136492\<0.0011.58 (0.49-5.04)^\*^1139/136400.763.09 (1.38-6.92)2278/272889\<0.0011.53 (0.60-3.92)^\*^Renal in HWE3937/1018\-\--991/107600.421.00 (0.69-1.47)993/107600.61.04 (0.71-1.52)993/1076\-\--1986/215200.781.07 (0.74-1.55)Lung3405/48100.875.42 (2.74-10.70)466/55500.571.72 (1.22-2.41)509/56600.462.14 (1.56-2.94)509/56600.794.52 (2.31-8.83)1018/113200.482.27 (1.74-2.95)Colorectal2545/2327\-\--554/2336\-\--554/233600.450.97 (0.57-1.63)554/2336\-\--1108/4672\-\--Pancreatic2255/391\-\--319/423820.021.61 (0.24-10.76)^\*^322/423630.13.14 (1.99-4.97)322/423\-\--644/84600.423.08 (1.98-4.78)Other7593/1377\-\--642/137774\<0.0011.53 (0.65-3.59)^\*^644/137772\<0.0011.57 (0.70-3.53)^\*^644/1377\-\--1288/2754690.011.57 (0.75-3.30)^\*^EthnicityAsian153607/4263130.333.50 (2.05-5.98)4010/461474\<0.0011.44 (1.04-1.99)^\*^4063/463076\<0.0011.49 (1.07-2.08)^\*^4063/463000.453.12 (1.83-5.32)8126/926077\<0.0011.49 (1.08-2.05)^\*^Caucasian131829/435700.696.63 (3.11-14.12)1926/445081\<0.0011.36 (0.58-3.19)^\*^1948/446082\<0.0011.45 (0.69-3.04)^\*^1948/446000.494.21 (2.04-8.71)3896/892075\<0.0011.65 (0.84-3.24)^\*^Caucasian in HWE121750/410800.7412.40 (2.19-70.22)1794/4172680.011.10 (0.48-2.49)^\*^1802/4172670.011.22 (0.62-2.37)^\*^1802/417200.7911.37 (2.02-63.93)3604/8344680.011.65 (1.17-2.32)^\*^Source of controlHB133197/3945450.121.54 (0.35-6.70)3510/423477\<0.0011.37 (0.92-2.05)^\*^3554/424879\<0.0011.40 (0.93-2.11)^\*^3554/4248350.193.13 (1.74-5.62)7108/849679\<0.0011.38 (0.93-2.05)^\*^PB173133/5705660.0111.55 (6.62-20.12)^\*^3295/588278\<0.0011.51 (0.88-2.58)^\*^3563/619485\<0.0011.90 (1.06-3.39)^\*^3563/6194690.00210.27 (2.42-43.63)^\*^6726/1178889\<0.0012.25 (1.18-4.29)^\*^PB in HWE163054/5456670.00615.51 (2.53-94.94)^\*^3163/5604600.011.34 (0.85-2.11)^\*^3417/590681\<0.0011.71 (0.97-3.03)^\*^3417/5906660.00714.20 (2.38-84.61)^\*^6434/1121289\<0.0012.33 (1.91-2.84)^\*^HWE: Hardy-Weinberg Equilibrium; PB: population based; HB: hospital based; Phet: P value for heterogeneity. ^\*^Random-effects model was used when P value for heterogeneity test \<0.05; otherwise, fixed-effects model was used.Figure 3**Overall association between the HIF-1α G1790A polymorphism and cancer risk for all subjects using the dominant model (GA + AA vs. GG).**

Test of heterogeneity {#Sec10}
---------------------

There was significant heterogeneity observed in the allelic comparison model, the dominant comparison model and the heterozygote comparison model (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}), and the heterogeneity was effectively decreased or removed in the subgroups stratified by ethnicity, cancer types and source of controls (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}).

Sensitivity analysis {#Sec11}
--------------------

We performed sensitivity analysis by removing each individual study (including the restudies with controls not in HWE) sequentially for both the HIF-1α C1772T and the HIF-1α G1790A polymorphism (Figure [4](#Fig4){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}). The results indicated that the overall significance of the pooled ORs was not altered by any single study in the genetic models for the HIF-1α C1772T/G1790A polymorphisms and cancer susceptibility, suggesting stability and reliability in our overall results.Figure 4**The influence of individual studies on the summary odds ratio (OR) for the HIF-1α G1790A polymorphism.**

Bias diagnostics {#Sec12}
----------------

A Begg's funnel plot and Egger's test were used to assess the publication bias in this meta-analysis. As shown in Figure [5](#Fig5){ref-type="fig"}, for the HIF-1α C1772T polymorphism, the funnel plots for the comparison of the five models appear to be basically symmetric. The Egger's linear regression test did not show any evidence of significant publication bias in five models (TT *vs.* CC: t = 0.50, *P* = 0.62; TC *vs.* CC: t = -0.19, *P* = 0.85; TT *vs.* CT + CC: t = 1.11, *P* = 0.28; T *vs.* C: t = 1.39, *P* = 0.17; CT + TT *vs*. CC: t = 0.59, *P* = 0.56). For the HIF-1α G1790A polymorphism, no visual publication bias was detected in the funnel plot (Figure [6](#Fig6){ref-type="fig"}) and the result showed no significant evidence of a publication bias in five models(AA *vs.* GG: t = 0.03, *P* = 0.98; GA *vs.* GG: t = -0.86, *P* = 0.40; AA *vs.* GA + GG: t = 0.33, *P* = 0.75; AA + AG *vs.*GG: t = -0.40, *P* = 0.69; A *vs.* G: t = -0.41, *P* = 0.68).Figure 5**Begg's funnel plot for evaluating the publication bias of the meta-analysis for the HIF-1α C1772T polymorphism.**Figure 6**Begg's funnel plot for evaluating the publication bias of the meta-analysis for the HIF-1α G1790A polymorphism.**

Discussion {#Sec13}
==========

HIF-1 is a heterodimeric transcription factor and a key regulator of the cellular response to hypoxia \[[@CR5]\]. It is composed of HIF-1α and HIF-1β subunits, which are members of the bHLH-PAS transcription factor family. HIF-1α is a unique O~2~-regulated subunit that determines the function of HIF-1. HIF-1α upregulates the expression of genes whose protein products function to increase O~2~ availability or to allow metabolic adaptation to O~*2*~ deprivation, including VEGF, Epo, NOS2 and others. Most of these aforementioned proteins have been implicated in tumor development and progression \[[@CR35], [@CR64], [@CR65]\]. Recent studies have reported that the overexpression of HIF-1α is significantly associated with cell proliferation, tumor susceptibility, tumor size, lymph node metastasis and prognosis \[[@CR12], [@CR35], [@CR66]\]. The HIF-1α gene is located on chromosome 14q21-24 and contains a total of 35 common SNPs, according to the dbSNP database (<http://www.ncbi.nlm.nih.gov/SNP>). Two polymorphisms, C1772T (rs11549465) and G1790A (rs11549467), result in an amino acid substitution of proline to serine and alanine to threonine, respectively, and the present studies show that C1772T (rs11549465) is not in substantial linkage disequilibrium (LD) with G1790A (rs11549467) (R^2^ = 0.002). Under normoxic condition, the hydroxylation of proline 402 and proline 564 occurs within the oxygen-dependent degradation (ODD) domain of HIF-1α, and HIF-1α is rapidly degraded. The two SNPs examined here are located within the ODD/pVHL binding domain in exon 12 of the HIF-1α gene and may enhance the transcription activity of the HIF-1α gene by causing structural changes, increasing the stability of HIF-1α protein and affecting the expression of downstream target genes \[[@CR8], [@CR14], [@CR17]\]. Over the last few years, a great number of studies have been performed to investigate the association between these HIF-1α polymorphisms and cancer risk in different populations. However, the results of these studies remain inconclusive. In a meta-analysis conducted by Zhao *et al.* in 2009 \[[@CR67]\], the HIF-1 C1772T polymorphism was reported to be associated with increased cancer risk, while no significant association was found between the HIF-1α G1790A polymorphism and cancer risk. Additionally, Li *et al.* reported that the HIF-1α C1772T polymorphism correlates with urinary cancer risk in Caucasian population, and the G1790A polymorphism may increase the risk of prostate cancer \[[@CR68]\]. Due to the important role of HIF-1α polymorphisms in the development of cancer and due to the limited statistical power of the previous studies, we conducted a comprehensive literature search and performed a meta-analysis on all of the available case-control studies to systematically evaluate the exact relationship between the C1772T/G1790A polymorphisms in HIF-1α and cancer susceptibility.

Regarding the HIF-1α C1772T polymorphism, our results suggested a significant association in four genetic comparison models, providing convincing evidence that the HIF-1α C1772T polymorphism may be a risk factor in cancer development. When sensitivity analyses were performed, the results were similar to those when the studies with controls not in HWE were included, suggesting that our results were very robust. Moreover, when the data were stratified by cancer type, a significant association was observed between the C1772T polymorphism and breast cancer in Asians. This may be due to the specific genetic variant induced over-expression of HIF-1 under hypoxic condition in breast cancer cells, and the different life style, ethnicity and body composition between Asians and Caucasians, which could contribute to the results. A significant association was also observed in lung cancer. When subgroup analyses were performed according to ethnicity and source of controls, a significant association was found in Asian population, Caucasian population and in hospital-based studies. Zhao *et al.* \[[@CR67]\] reported that the genotype TT was significantly associated with an increased cancer risk in Asians, but the CI was very wide due to the lack of mutant homozygotes in Asians. In our meta-analysis, we also found that the C1772T polymorphism was a risk factor in Asians (Dominant model: OR = 1.29, 95% CI = 1.04-1.58; Allelic model: OR = 1.47, 95% CI = 1.04-1.57). Beyond that, we had not found any significant associations in prostate cancer, renal cancer or oral cancer.

For the HIF-1α G1790A polymorphism, the pooled results from all of the eligible studies suggested that the G1790A polymorphism in HIF-1α is significantly associated with an increased cancer risk in all of the genetic models. We also conducted subgroup analyses based on the cancer type, ethnicities and source of controls. In the subgroup analysis according to cancer type, the results suggested that the HIF-1α G1790A polymorphism significantly increased the risk of lung cancer, renal cancer, oral cancer and pancreatic cancer, but the CI for the oral cancer subgroup was very wide. This may be due to the lack of mutant homozygotes detected, and the association could have been caused by chance. More studies based on large populations should be prusued. The study reported by Putra *et al.* indicated that even though they did not found any significant differences in genotype for G1790A between lung cancer patients and healthy controls, however, the G1790A variant allele was significantly higher in lung cancer patients, and TP53 LOH and 1p34 LOH were more frequently observed in individuals with the HIF-1α G1790A polymorphism, suggesting that this polymorphism may induce mutations in some tumor suppressor genes involved in lung cancer development \[[@CR46]\]. Here, we found a significant association between the G1790A polymorphism and lung cancer risk. When the data were stratified according to ethnicity classification and source of controls, similar to the C1772T polymorphism, significantly increased risks were also found in Asian populations, Caucasian populations and population-based studies. After sensitivity analyses were performed, our results did not vary substantially, which strongly suggests an association between the HIF-1α G1790A polymorphism and increased cancer risk. One important factor that could influence the results is heterogeneity. In our study, significant heterogeneity existed in the analysis of the heterozygote model, the dominant model and the allelic model for the HIF-1α C1772T/G1790A polymorphism. When we performed a subgroup analysis according to cancer type, ethnicity or source of controls, the heterogeneity was reduced significantly or disappeared. The significant heterogeneity may due to the differences in ethnicity or cancer types or even in the selection of the controls. Furthermore, publication bias was not observed in our meta-analysis of the HIF-1α G1790A/C1772T polymorphisms. We also performed a sensitivity analysis to evaluate the sources of heterogeneity. The pooled ORs did not vary substantially, indicating that the results of our meta-analysis are robust and reliable.

To a certain extent, our meta-analysis still includes several limitations that should be interpreted and taken into consideration. First, in the era of GWAS, researchers can obtain the GWAS data for these two SNPs from all cancer studies and conduct a meta-analysis with the GWAS data instead of relying on published data, which may be biased toward positive findings. Second, the lack of observations concerning gene-gene and gene-environment interactions could influence our results. Third, although the total number of studies was not small, there were still not sufficient eligible studies for us to analyze different types of cancers, such as colorectal carcinoma, renal cell carcinoma or glioma; more studies are needed to explore the potential relationship between HIF-1αC1772T/G1790A polymorphisms and cancer susceptibility. Forth, the lack of detailed original data, such as the age and sex of the populations, smoking status, or alcohol consumption in the eligible studies may influence our extended analyses. However, our meta-analysis also has many advantages. First, we searched all possible publications, and the total number of eligible studies was much larger than other previously published meta-analyses; therefore, our results are more convincing. Second, no publication bias was detected in our meta-analysis. Finally, all of the data were extracted from well-selected studies, providing stronger statistical power for our study.

Conclusions {#Sec14}
===========

In conclusion, this meta-analysis provides powerful evidence that both the C1772T and G1790A polymorphisms in the HIF-1α gene may contribute to individual susceptibility to cancers. It will be necessary to perform additional research to evaluate the relationship between HIF-1α C1772T/G1790A polymorphisms and cancer risk. Moreover, large sample case-control studies assessing gene-to-gene and gene-to-environment interactions are required to verify these findings.
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